Skip to main content
Premium Trial:

Request an Annual Quote

RNA Disease Diagnostics to Develop Point-of-Care Coronavirus Test With Newly Licensed Tech

NEW YORK — RNA Disease Diagnostics said on Thursday that it has acquired an exclusive worldwide license to a diagnostic technology — owned by the University of Maryland, Baltimore and the University of Maryland, Baltimore County — that it will use to develop a rapid, point-of-care for SARS-CoV-2.

According to the company, the technology uses antisense oligonucleotides to detect infectious disease gene sequences and can provide results within 45 minutes. It will initially use the technology to develop a point-of-care test for SARS-CoV-2, followed by a home-use test.

Additional details about the technology or the license were not disclosed.

"Licensing this promising sensor technology from the universities enables us to advance a diagnostic test that may serve as a future gold standard in accurate and rapid COVID-19 testing," RNA Disease Diagnostics Cofounder and Chairman Allan Oberman said in a statement.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.